Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625490 · ClinicalTrials.gov registry record · Early Phase 1
Myocardial Perfusion Imaging Galmydar Rest/Stress
A Early Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
NCT05625490 is a Early Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 15 participants.
The verdict
NCT05625490, a Early Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
A single center, phase 0/1 clinical imaging study designed to assess the role of \[68Ga\]Galmydar PET/CT imaging in human subjects.
Interventions
- DRUG Ga-68 Galmydar
- DRUG 13N-ammonia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2025-12-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05625490
The ClinicalTrials.gov registry entry for NCT05625490 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ga-68 Galmydar is the first listed.
NCT05625490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05625490 about?
NCT05625490 is a clinical study titled "Myocardial Perfusion Imaging Galmydar Rest/Stress". A single center, phase 0/1 clinical imaging study designed to assess the role of \[68Ga\]Galmydar PET/CT imaging in human subjects.
What is the current status of trial NCT05625490?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2022-11-11. Estimated completion is 2025-12-19.
What interventions are being tested in trial NCT05625490?
The interventions under investigation include: Ga-68 Galmydar (DRUG), 13N-ammonia (DRUG).
Who is sponsoring clinical trial NCT05625490?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.